Author Archives: Amanda Suttle

Eppendorf BioBLU® 10c Single-Use Vessels Simplify Handling of Cell Culture Bioprocesses at Bench Scale

Substituting traditional glass bioreactors with single-use equipment can simplify a bioprocess workflow. Implementing single-use vessels eliminates the need for cleaning and autoclaving, thus reducing the time needed to prepare a bioprocess run and lowering contamination risk. Another advantage is that single-use vessels reduce occupational hazards associated with overweight handling (especially at larger bench scales) because plastic weighs less than glass. Fill out the form below to read the complete white paper now.

Cell Culture Bioprocessing in Perfusion: Assessing Cell Retention Technologies

Upstream bioprocessing in perfusion mode holds great promise for industrial production of cells and biologics. In perfusion, fresh medium is added constantly to the bioreactor, and used medium is harvested while the cells are retained in the bioreactor. As a result, the composition of the cell culture medium stays quite constant during the process. This offers several advantages. In perfusion, higher cell densities can be reached than in batch and fed-batch processes, therefore enhancing volumetric productivity. Because medium composition can…

Comparing Culture Methods in Monoclonal Antibody Production: Batch, Fed-Batch, and Perfusion

Recombinant protein manufacturing with Chinese hamster ovary (CHO) cells represents over 70% of the entire biopharmaceutical industry (1). In fact, human monoclonal antibodies (hMAbs) produced by CHO cells have played a major role in both the diagnostic and therapeutic markets for decades. One of the first human–mouse chimeric MAbs to obtain FDA approval was Roche’s rituximab treatment for non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis. Since that approval in 1997, scores of chimeric, humanized, and human MAbs have gained…